Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4000223 | 0.90 | CNR2 (0.64) | CNR2CNR1 | |
| SCHEMBL3365306 | 0.86 | CNR2 (0.51) | CNR2CNR1 | |
| SCHEMBL4764521 | 0.86 | CNR2 (0.64) | CNR2CNR1 | |
| SCHEMBL3999530 | 0.85 | CNR2 (0.52) | CNR2CNR1 | |
| SCHEMBL4000508 | 0.83 | CNR2 (0.68) | CNR2CNR1 | |
| SCHEMBL3999197 | 0.82 | CNR2 (0.56) | CNR2CNR1 | |
| SCHEMBL3144800 | 0.81 | CNR2 (0.79) | CNR2CNR1 | |
| SCHEMBL3999313 | 0.80 | CNR2 (0.48) | CNR2CNR1 | |
| SCHEMBL13980913 | 0.79 | CNR2 (0.52) | CNR2CNR1 | |
| SCHEMBL3999393 | 0.78 | CNR2 (0.52) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598393-B2 | Sulfonyl benzimidazole derivatives | PFIZER INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-1809607-B1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | PFIZER (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20060094750-A1 | Sulfonyl benzimidazole derivatives | KON-I KANA | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094750-A1 | Sulfonyl benzimidazole derivatives | TRPV1, CNR2, CNR1 | CNR2 2/4885CNR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.